Eligibility for somatostatin receptor (SSTR) radionuclide therapy uses the qualitative
Krenning score based on 111In-pentetreotide planar scintigraphy as was performed in the …

Neuroendocrine tumors (NETs) possess unique features including expression of peptide
hormone receptors as well as the capacity to concentrate and take up precursor forms of …

Background Somatostatin analog functional imaging with gallium‐68 (Ga‐68) dotatate
positron emission tomography/computed tomography (PET/CT) has demonstrated …

Because of the presence of cell membrane somatostatin receptors (SSTRs), many
neuroendocrine tumors will bind analogs of somatostatin. 90Y-Dodecanetetraacetic acid …

Sufficient expression of somatostatin receptor (SSTR) in well-differentiated neuroendocrine
tumours (NETs) is crucial for treatment with somatostatin analogues (SSAs) and peptide …

Purpose Precise determination of neuroendocrine tumor (NET) disease status and response
to therapy remains a rate-limiting concern for disease management. This reflects limitations …

Neuroendocrine tumors (NETs) express somatostatin receptors (SSTRs) 2 and 5. Modified
variants of somatostatin, the cognate ligand for SSTR2 and SSTR5, are used in treatment for …

Somatostatin receptors (SSTR) are upregulated in the cells of origin that define numerous
neuroendocrine neoplasms. PET imaging with 68 Ga-DOTATATE allows specific targeting of …

Neuroendocrine neoplasms (NENs) encompass a broad spectrum of tumors throughout the
body and range in biologic behavior from indolent to aggressive. Consequently, a wide …

The aim of this study was to evaluate the diagnostic value of a new somatostatin analog,
68Ga-labeled 1, 4, 7, 10-tetraazacyclododecane-N, N′, N ″, N ″′-tetraacetic acid-d …